Ex vivo identification and characterization of a population of CD13high CD105+ CD45- mesenchymal stem cells in human bone marrow by Muñiz, C. (Carmen) et al.
Muñiz et al. Stem Cell Research & Therapy  (2015) 6:169 
DOI 10.1186/s13287-015-0152-8RESEARCH Open AccessEx vivo identification and characterization
of a population of CD13high CD105+ CD45−
mesenchymal stem cells in human bone marrow
Carmen Muñiz1,2†, Cristina Teodosio1,3†, Andrea Mayado1, Ana Teresa Amaral4, Sergio Matarraz1, Paloma Bárcena1,
Maria Luz Sanchez1, Iván Alvarez-Twose5, María Diez-Campelo6, Andrés C. García-Montero1, Juan F. Blanco2,7,
Maria Consuelo Del Cañizo6, Javier del Pino Montes2,8† and Alberto Orfao1,9*†Abstract
Introduction: Mesenchymal stem cells (MSCs) are multipotent cells capable of self-renewal and multilineage
differentiation. Their multipotential capacity and immunomodulatory properties have led to an increasing interest
in their biological properties and therapeutic applications. Currently, the definition of MSCs relies on a combination of
phenotypic, morphological and functional characteristics which are typically evaluated upon in vitro expansion, a
process that may ultimately lead to modulation of the immunophenotypic, functional and/or genetic features of these
cells. Therefore, at present there is great interest in providing markers and phenotypes for direct in vivo and ex vivo
identification and isolation of MSCs.
Methods: Multiparameter flow cytometry immunophenotypic studies were performed on 65 bone marrow (BM)
samples for characterization of CD13high CD105+ CD45– cells. Isolation and expansion of these cells was performed in
a subset of samples in parallel to the expansion of MSCs from mononuclear cells following currently established
procedures. The protein expression profile of these cells was further assessed on (paired) primary and in vitro
expanded BM MSCs, and their adipogenic, chondrogenic and osteogenic differentiation potential was also
determined.
Results: Our results show that the CD13high CD105+ CD45− immunophenotype defines a minor subset of cells
that are systematically present ex vivo in normal/reactive BM (n = 65) and that display immunophenotypic features,
plastic adherence ability, and osteogenic, adipogenic and chondrogenic differentiation capacities fully compatible with
those of MSCs. In addition, we also show that in vitro expansion of these cells modulates their immunophenotypic
characteristics, including changes in the expression of markers currently used for the definition of MSCs, such as CD105,
CD146 and HLA-DR.
Conclusions: BM MSCs can be identified ex vivo in normal/reactive BM, based on a robust CD13high CD105+ and
CD45− immunophenotypic profile. Furthermore, in vitro expansion of these cells is associated with significant
changes in the immunophenotypic profile of MSCs.* Correspondence: orfao@usal.es
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Mesenchymal stem cells (MSCs) are nonhematopoietic
multipotent stem cells that have the ability for self-
renewal and multilineage differentiation [1]. These cells
were first described as residing in the bone marrow
(BM), which is currently the most extensively studied
source for MSCs; however, MSCs have also been success-
fully isolated from tissues other than BM (e.g., umbilical
cord blood [2], the placenta [3], amniotic fluid [4], adipose
tissue [5], lung [6], skeletal muscle [7] and the dental pulp
[8]). Due to their multipotential capacity [1] and immuno-
modulatory properties [9, 10], an increasing interest has
emerged about the biological properties and the potential
clinical application of these cells, as they may represent a
potential source for cell-based therapy for tissue repair
[11, 12] and for suppressing autoimmunity [13]. In
addition, MSCs may also play an important role in the
pathogenesis of several diseases, including hematological
disorders such as multiple myeloma [14], chronic myeloid
leukemia [15] and myelodysplastic syndromes [16, 17].
At present, the identification and definition of MSCs are
both based on a combination of phenotypic, morpho-
logical and functional characteristics, summarized into
three minimal criteria by the International Society for Cel-
lular Therapy (ISCT) [18]. Based on these criteria, MSCs
must lack expression of hematopoietic markers (CD19 or
cyCD79a, CD11b or CD14, CD45, CD34 and HLA-DR),
and show positivity for several other proteins (CD73,
CD90 and CD105). Furthermore, MSCs must also be cap-
able of adhering to a plastic surface when maintained in
standard culture conditions, and to differentiate to at least
three different cell lineages (i.e., osteoblastic, adipocytic
and chondrocytic lineages) [18].
Despite the above criteria have contributed to the
standardization of MSC studies, the need for in vitro
expansion of these cells prior to their characterization has
been suggested to potentially modify their immunopheno-
typic, functional or even genetic features during culture
[17, 19–22]; such changes could contribute to explain, at
least in part, discrepant results observed in the literature
about the characteristics of MSCs [17, 22–27]. Therefore,
at present there is a great interest in providing markers for
direct in vivo and ex vivo identification and isolation of
MSCs [28–31]. In this regard, several studies have identi-
fied markers that could be used for positive selection of
BM MSCs, such as the nerve growth factor receptor
(CD271), the mesenchymal stem cell antigen 1 (MSCA-1),
STRO-1, SSEA-4 and the CD13 ectoenzyme [32–34], in
addition to CD73, CD90 and CD105. However many of
these markers do not provide a clear-cut distinction
between MSCs and other BM cells; due to their heteroge-
neous expression, their overlap with other BM cell popula-
tions, or the fact that they have not been systematically
used for the identification of MSCs.In the present study we identified (ex vivo) the
CD13high CD105+ CD45– immunophenotype to define a
minor population of BM cells that show immunopheno-
typic, morphologic and functional features which are
fully compatible with those of MSCs. Further compari-
son of the ex vivo immunophenotypic features of such
BM MSCs versus those of in vitro expanded MSCs, ob-
tained either through standard isolation procedures or
by flow cytometry-based sorting of CD13high CD105+
CD45– cells, showed that the immunophenotypic pro-
file of MSCs undergoes significant changes during
in vitro expansion, such changes including downregula-
tion of CD10, CD13 and HLA-DR and upregulation of
CD105 and CD146.
Materials and methods
BM samples
A total of 65 freshly obtained ethylenediaminetetraacetic
acid (EDTA)- or heparin-anticoagulated normal (n = 9)
and reactive (n = 56) BM aspirates were obtained from
an identical number of individuals (30 males and 35
females; median age 51 years, range 22–76 years) at the
University Hospital of Salamanca, Spain, and the Mast
Cell Unit of the Hospital Virgen del Valle, Toledo, Spain.
Normal BM samples were obtained from healthy donors,
while reactive samples corresponded to patients undergo-
ing BM aspiration due to suspected mastocytosis or other
hematological disorders, but who did not exhibit any
clonal hematological disease. The study was approved by
the local Ethics Committee, Comisión de Bioética del
Centro de Investigación del Cáncer—IBMCC (USAL-
CSIC). In all cases, informed consent was obtained prior
to the study, according to the guidelines of the local Ethics
Committee, and all experiments were performed following
the Declaration of Helsinki.
Ex vivo multiparameter flow cytometry
immunophenotypic studies
Multiparameter flow cytometry (MFC) immunophenoty-
pic studies were performed on BM aspirated samples,
processed under sterile conditions within the first 24
hours after they were collected. For ex vivo immunophe-
notypic characterization of BM MSCs, a direct immuno-
fluorescence stain-and-then-lyse technique was used, as
previously described in detail [35]. Eight color combina-
tions of monoclonal antibodies (MoAb) were used to
identify and characterize BM MSCs (Additional file 1:
Table S1). For each sample, a minimum of 1.5 × 106 cells
were analyzed per antibody combination using a FACS-
Canto II flow cytometer (Becton Dickinson Biosciences,
San Jose, CA, USA) equipped with the FACSDiva soft-
ware (Becton Dickinson). Identification of MSCs was
performed based on CD13high and CD105+ expression in
the absence of CD45 and high but heterogeneous light
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software (Cytognos SL, Salamanca, Spain) was used.
Expression of individual markers was recorded both as
percentage of positive cells and as median fluorescence
intensity (MFI; arbitrary fluorescence units scaled from 0
to 262,000) after subtracting the baseline autofluorescence
levels observed for MSCs in the corresponding fluores-
cence detector.Fig. 1 Representative bivariate dot plots and single parameter histograms
characteristics of bone marrow CD13high CD105+ CD45– cells. a–h Gating s
on their unique CD13high CD105+ CD45– and high but heterogeneous ligh
CD13high CD105+ CD45– cells from a representative healthy donor. Baseline
in the histogram plot in gray and black, respectively, using the overlay histo
median fluorescence intensity (arbitrary units scaled from 0 to 262,000)MSC isolation, expansion and culture
Isolation and expansion of MSCs was performed on 14
heparin-anticoagulated BM samples. Prior to mono-
nuclear cell (MNC) isolation, autologous BM plasma was
obtained by centrifugation for (10 minutes at 1200 g). Low
density BM MNC were then isolated using a Biocoll
density gradient centrifugation step (Biochrom AG,
Berlin, Germany). Afterwards, MNC were washed andillustrating the gating strategy and the ex vivo immunophenotypic
trategy used for the identification of these bone marrow cells based
t scatter features. i–t Immunophenotypic features of bone marrow
autofluorescence and expression levels for each protein are indicated
gram function of the Infinicyt software. SSC sideward light scatter, MFI
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mented with 10 % fetal bovine serum (FBS; Gibco, Life
Technologies, Paisley, UK). To isolate CD13high CD105+
CD45– cells (i.e., MSC fraction), a four-way fluorescence-
activated cell sorter (FACSAria, Becton Dickinson)
equipped with the FACSDiva software was used. Before
sorting, cells were stained with the CD45 pacific orange
(PacO)/CD105 fluorescein isothiocyanate (FITC)/CD73
phycoerythrin (PE)/CD34 peridinin chlorophyll protein
(PerCP)–cyanin 5.5 (Cy5.5)/CD117 PE–cyanin 7 (Cy7)/
CD13 allophycocyanin (APC) combination of MoAbs for
30 minutes at 4 °C in the dark. Based on this MoAb com-
bination, MSCs were identified and sorted as SSChi
CD13high CD73+ CD105+ CD45– CD34– CD117– cells
with a purity systematically ≥95 %. In addition, those cells
which did not meet the phenotypic criteria for CD13high
CD105+ CD45– cells (i.e., non-MSCs) were also isolated;
in this later fraction (non-MSC cell fraction) no contamin-
ation (<0.01 %) by cells phenotypically compatible with
MSCs was detected. The sorted non-MSC and MSC frac-
tions were separately resuspended in Dulbecco’s modified
Eagle’s medium (DMEM; Sigma-Aldrich, Steinheim,
Germany) supplemented with 20 % autologous plasma,
L-glutamine 2 mM and 1 % penicillin-streptomycin
(Gibco), and plated in six-well culture plates (Corning
Inc., Corning, NY, USA). In parallel, isolation of MSCs
using conventional MSC expansion after in vitro culture
was also performed, as described elsewhere [1, 36]. Briefly,
MNCs were resuspended in DMEM medium supple-
mented with 15 % FBS, L-glutamine 2 mM and 1 %
penicillin-streptomycin, and plated in six-well culture
plates at a concentration of 1 × 106 cells/well. Culture
plates were maintained in a humidified atmosphere
with 5 % CO2 at 37 °C. After 4 days of cell culture (for
both purified MSCs and MNCs), nonadherent cells
were removed and fresh medium (DMEM plus 15 %
FBS, L-glutamine 2 mM and 1 % penicillin-strepto
mycin) was added; for the sorted non-MSC fraction,
cultured cells were washed and the culture medium
replaced. These steps were then repeated every 2 days
until the culture reached 80 % cell confluence. At this
moment, nonadherent cells were discarded while
adherent cells were detached with 0.05 % trypsin/
EDTA (Gibco) and plated again in two or three culture
flasks. This later procedure was repeated every 2 days,
three times, in order to ensure that contaminating
hematopoietic cells had been washed out of the cell
culture.
Adipogenic, chondrogenic and osteogenic in vitro
differentiation of MSCs
In order to fulfill the ISCT criteria for the definition of
MSCs [18], adipogenic, osteogenic and chondrogenic
differentiation was performed on both sorted MSCs andMNC-derived MSCs, as previously described [17, 37].
Briefly, MSCs were resuspended and plated in a 24-well
culture plate at a concentration of 1 × 104 cells/well with
either conditioned (differentiation) medium or with
standard growth medium (DMEM plus 15 % FBS, L-
glutamine 2 mM and 1 % penicillin-streptomycin); fresh
medium was added every 2 days. To induce adipogenic
differentiation, cells were incubated for 8 days with the
STEMPRO® Adipogenesis Differentiation Kit medium
(Invitrogen Life Science, Grand Island, NY, USA),
according to the manufacturer’s instructions. The pres-
ence of neutral lipids was visualized by standard staining
with Oil Red O (Sigma-Aldrich, St. Louis, MO, USA)
[38]. In parallel, cells were also grown in osteogenic
induction medium (STEMPRO® Osteogenesis Differenti-
ation Kit medium (Invitrogen Life Sciences)) to induce
osteogenic differentiation. Detection of osteoblasts was
performed both after 8 days of culture using alkaline
phosphatase staining [39], and after 11 days of culture
through demonstration of the presence of calcium de-
posits using the alizarin red S (Sigma-Aldrich) staining
[40]. To induce chondrogenesis, 2.5 × 104 cells were
placed in a 15-ml polypropylene tube and centrifuged
(150 g for 10 minutes) in order to form a pelleted cellu-
lar micromass at the bottom of the tube. The cell pellet
was cultured in 500 μl chondrogenic induction medium
(STEMPRO® Chondrogenesis Differentiation Kit medium)
following the recommendations of the manufacturer.
Fresh chondrogenic differentiation medium was added
every 2 days; after 27 days, the micromass was fixed,
embedded in paraffin, cut in a microtome and stained
with toluidine blue (Sigma-Aldrich) [41].
Multiparameter flow cytometry immunophenotypic
studies of in vitro expanded MSCs
For the assessment of the phenotype of in vitro
expanded MSCs (i.e., the expression of those proteins
previously evaluated on ex vivo MSCs) a direct im-
munofluorescence technique was used as previously
described in detail [42]. Briefly, 2 × 105 cells were
stained (30 minutes at 4 °C in the dark) with eight-color
combinations of MoAbs (Additional file 1: Table S1);
stained cells were subsequently measured in a FACS-
Canto II flow cytometer equipped with the FACSDiva
software.
Statistical analyses
For all continuous variables, their median, mean, stand-
ard deviation, range and both the 25th and 75th, and
the 10th and 90th percentiles, were calculated; for cat-
egorical variables, frequencies were reported. Statistical
significance (P value ≤0.05) was determined by the
non-parametric Kruskal-Wallis and Mann-Whitney U
tests (for continuous variables in case of independent
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ric tests for paired samples. For all statistical analyses
the SPSS 18.0 software (SPSS, Chicago, IL, USA) was
used.Results
Frequency and ex vivo immunophenotypic features of
CD13high CD105+ CD45– cells in normal and reactive BM
samples
Overall, a CD13high CD105+ CD45– cell population was
identified in every BM sample analyzed. Such cells were
present at relatively low frequencies (median 0.028 %;
range 0.0004–0.61 %) in all BM samples studied. Over-
all, they showed high but heterogeneous light scatter
features, associated with lack of expression of early
hematopoietic cell markers (CD34–, CD45–, CD117–),
monocyte–macrophage related proteins (CD11b–, CD14–)
and B cell lineage markers (CD19–) (Table 1 and Fig. 1).
Conversely, expression of classical MSC-related markers
(CD73, CD90, CD105 and CD146) was systematically ob-
served in this cell compartment for all BM samples ana-
lyzed. Despite the above markers being detected in the
whole CD13high CD105+ CD45– cell population (100 % of
the cells; Table 1), different expression levels for individual
antigens were observed for distinct markers; thus, CD146
was typically dimly expressed, whereas the pattern of ex-
pression of CD90 was heterogeneous among different
samples (normalized MFI ranging from 1870 to 260,738
arbitrary fluorescence units), as well as among cells
from individual samples (Fig. 1). Expression of CD105
and CD73 was also detected in 100 % of the cells with
homogeneously positive-to-moderate positive expres-
sion levels (Fig. 1). Reactivity for CD10 and HLA-DR
were heterogeneous and typically restricted to only a
subset of the whole CD13high CD105+ CD45– cell popu-
lation (62 % to 97 % and 50 % to 100 % of the CD13high
CD105+ CD45– cells, respectively). Expression of other,
more recently described, MSC-associated markers
(nerve growth factor receptor (CD271), MSCA-1,
SSEA-4 and STRO-1) was also assessed in a smaller
subset of samples (n = 5). In these samples, co-
expression of CD271, MSCA-1, SSEA-4 and STRO-1 was
also systematically observed on CD13high CD105+ CD45–
cells (Additional file 2: Figure S1). Nevertheless, whereas
CD271 and MSCA-1 were strongly expressed on these
cells, expression of STRO-1 was heterogeneous and
SSEA-4 was only dimly expressed (Additional file 2:
Figure S1).
Of note, with the exception of the expression of CD90,
which was significantly decreased in reactive (versus
normal) samples, no differences were observed between
normal and reactive BM MSCs for all other markers
analyzed (Table 2).In vitro expansion, and osteogenic, adipogenic, and
chondrogenic differentiation of CD13high CD105+
CD45– cells
Since the CD13high CD105+ CD45– BM cell population
showed immunophenotypic features which were com-
patible with those of MSCs [18], we aimed to determine
whether these cells also displayed the minimal functional
criteria for MSCs (adherence to plastic and multipotent
differentiation potential to the osteogenic, adipogenic
and chodrogenic cell lineages), compared with donor-
matched MSCs isolated from the same BM by the con-
ventional method of density gradient purification
followed by plastic adherence. In order to demonstrate
that the CD13high CD105+ CD45– BM cell fraction con-
tained virtually all BM MSCs, the negative BM cell frac-
tion corresponding to all BM cells depleted on the
CD13high CD105+ CD45– cell population was also cul-
tured in parallel. Overall, both the FACS-sorted CD13high
CD105+ CD45− cells and conventional in vitro cultured
MSCs showed a similar ability to adhere to plastic; in
addition, no significant differences were found regarding
the growth rate of the two cells fractions (Fig. 2). In
contrast, no adherent cells were observed in the BM cell
fraction depleted from CD13high CD105+ CD45− cells at
the time when the former two cell populations reached an
80 % confluent layer (passage 1).
The multipotent differentiation potential of both
FACS-sorted CD13high CD105+ CD45– cells and MNC-
cultured MSCs was evaluated in parallel in five different
samples. Both fractions showed a normal osteogenic,
adipogenic and chondrogenic differentiation after three
passages, as assessed via: 1) determination of the alkaline
phosphatase activity and the detection of extracellular
calcium deposits using Alizarin Red staining (Fig. 3,
panels II–III) after 8 and 11 days of culture with condi-
tioned medium, respectively; 2) the Oil Red O staining
for detection of lipid droplets after 8 days of culture with
conditioned medium (Fig. 3, panel IV) and; 3) staining
for cartilaginous extracellular matrix performed with
toluidine blue after 27 days of culture with conditioned
medium (Fig. 3, panel V).
Immunophenotypic features of ex vivo and in vitro
expanded FACS-sorted CD13high CD105+ CD45− cells
versus MSCs obtained using conventional cell culture
methods
Once compared to donor-matched MSCs isolated from
BM MNCs by conventional plastic adherence methods,
in vitro expanded FACS-sorted CD13high CD105+ CD45–
cells showed similar immunophenotypic features. Thus,
they displayed similar levels of CD10, CD13, CD73,
CD90, CD105 and CD146, and at the same time both
cultured cell populations lacked CD11b, CD14, CD19,
CD34, CD45, CD117 and HLA-DR expression. In
Table 1 Ex vivo pattern of expression of individual markers on CD13high CD105+ CD45− cells from normal/reactive bone marrow
samples
Code Antigen Expression pattern % of positive
cellsa
Amount of protein
expressed/cellb(% of positive cases; positive cases/total cases)
CD10 Neprilysin −/+ 89 % 6916
(100 %; 18/18) (62–97 %) (1883–22,177)
CD11b Integrin alpha-M – NA NA
(0 %; 0/9)
CD13 Aminopeptidase N ++/+++ 100 % 122,414
(100 %; 60/60) (100–100 %) (45,582–260,438)
CD14 Myeloid Cell-Specific Leucine-Rich Glycoprotein – NA NA
(0 %; 0/47)
CD19 B-Lymphocyte Surface Antigen B4 – NA NA
(0 %; 0/37)
CD34 Hematopoietic Progenitor Cell Antigen-1 – NA NA
(0 %; 0/60)
CD45 Leukocyte common antigen – NA NA
(0 %; 0/60)
CD73 Ecto-5′-nucleotidase +/++ 100 % 7816
(100 %; 58/58) (100–100 %) (3268–23,090)
CD90 Thy-1 +/+++ 100 % 21,875
(100 %; 55/55) (100–100 %) (1870–260,738)
CD105 Endoglin + 100 % 2463
(100 %; 60/60) (100–100 %) (700–4620)
CD117 Kit – NA NA
(0 %; 0/54)
CD146 Melanoma cell adhesion molecule +Low 100 % 547
(100 %; 55/55) (100–100 %) (267–3054)
NA HLA-DR −/+ 91 % 3296
(100 %; 34/34) (50–100 %) (390–15,823)
Codes used for the intensity of expression of individual markers: (−) negative; (−/+) heterogeneous from negative to positive; (+Low) dim positive (median
fluorescence intensity (MFI) ≥250 and <1000); (+) moderate positive (MFI ≥1000 and <10,000); (++) positive (MFI ≥10,000 and <50,000); (+++) strong positive
(MFI ≥50,000). Mixed symbols indicate variable reactivity, either among different samples or among cells from the same sample
aResults expressed as median (range)
bNormalized MFI values (median (range)) calculated after subtracting the background autofluorescence levels observed for each individual marker-associated
fluorochrome and expressed as arbitrary units scaled from 0 to 262,000
NA not applicable
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CD13high CD105+ CD45– cells were compared with
donor-matched (recently obtained, noncultured) ex vivo
CD13high CD105+ CD45– BM cells, the former showed
significantly higher levels of CD105 (P = 0.03) and
CD146 (P ≤ 0.04) expression (Fig. 2f and g). In contrast,
expression of both CD10 and CD13, despite remaining
positive, was significantly decreased (P ≤ 0.04) after
in vitro culture of CD13high CD105+ CD45– cells (Fig. 2b
and c). Interestingly, expression of HLA-DR, which was
detected on ex vivo BM CD13high CD105+ CD45– cells,
was not detected on either of the two in vitro expanded
donor-matched MSC populations (P = 0.01) (Fig. 2h).Discussion
In recent years, growing interest has emerged about
MSCs due to their unique biological properties (e.g.,
their low immunogenicity, their immunomodulatory
properties, availability, self-renewal and differentiation
capacities) [1, 9, 43, 44] which make them a good candi-
date for cell therapy, as well as their involvement in the
pathogenesis of several diseases [14, 15, 17]. However,
the need for in vitro expansion of MNC fractions of BM
cells for the definition of MSCs (which may affect the nat-
ural properties of these cells) together with the lack of
(universally accepted) specific antigens and phenotypes
for their ex vivo identification and positive isolation, has
Table 2 Distribution and phenotypic profile of CD13high CD105+ CD45– cells in normal versus reactive bone marrow samples
Normal BM (n = 9) Reactive BM (n = 51)
Antigenic profile % positive cells MFI % positive cells MFI
% CD13high CD105+ CD45− cells 0.008 (0.0004–0.04) 0.03 (0.0007–0.6)*
CD10 91 % 7624 88 % 6916
(75–97 %) (2069–22,177) (62–97 %) (1883–14,821)
CD11b NA NA NA NA
CD13 100 % 162,716 100 % 114,760
(100–100 %) (58,223–260,438) (100–100 %) (45,582–182,771)
CD14 NA NA NA NA
CD19 NA NA NA NA
CD34 NA NA NA NA
CD45 NA NA NA NA
CD73 100 % 7241 100 % 8149
(100–100 %) (3268–23,090) (100–100 %) (4462–16,288)
CD90 100 % 64,102 100 % 17,729*
(100–100 %) (12,081–260,738) (100–100 %) (1870–108,409)
CD105 100 % 2598 100 % 2463
(100–100 %) (700–3420) (100–100 %) (1299–4620)
CD117 NA NA NA NA
CD146 100 % 733 100 % 502
(100–100 %) (292–2992) (100–100 %) (267–3054)
HLA-DR 98 % 4038 87 % 2589
(78–100 %) (390–11,726) (50–100 %) (407–15,823)
Results expressed as median (range) percentage of positive cells and MFI calculated after subtracting baseline autofluorescence levels
*P < 0.05 versus normal BM
BM bone marrow, MFI median fluorescence intensity (expressed as arbitrary fluorescence units scaled from 0 to 262,000), NA not appropriate (as these markers
were absent on CD13high CD105+ CD45− cells)
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tial markers/phenotypes and the establishment of spe-
cific strategies for accurate in vivo and ex vivo
identification of MSCs [28, 30]. In recent years, import-
ant advances have been achieved in this regard and sev-
eral markers such as CD271 and MSCA-1 have been
identified which can be used for purification of MSCs
[32, 45–47]. However, some of these markers are dimly
expressed and do not provide a sufficient definition of
MSCs versus other cells in the sample (e.g., SSEA-4 or
CD146) and/or their expression is not restricted to
MSCs (e.g., STRO-1 is also expressed by nucleated
erythroid cells) [32–34]. In addition, other markers
have been found to be associated to, but not specific of,
MSCs such as CD13, CD105 and CD90 [33, 34]. Here
we show that the CD13high CD105+ CD45– immuno-
phenotype defines a unique minor subset of BM cells
that display MSC features which can be detected
ex vivo on fresh BM aspirated samples prior to cell cul-
ture. Furthermore, we show that in vitro expansion of
these cells modulates their immunophenotypic charac-
teristics including the expression of markers currentlyused in the definition of MSCs; these results reinforce
the need for a more detailed ex vivo characterization of
MSCs.
In this study, CD13high CD105+ CD45– cells were sys-
tematically present in all normal/reactive BM samples
analyzed. In the BM samples studied, these cells repre-
sented a minor cell compartment which displayed a
unique and clearly different phenotype, distinct from
that of all BM cell populations described so far. There-
fore, these cells showed features distinct from those of
B cells (CD19–), monocyte/macrophage lineage cells
(CD11b–, CD14–), erythroid precursor cells (CD13hi,
CD73+/++, CD90+/+++), hematopoietic precursor cells
(CD34–, CD117–) and endothelial cells (CD34–), also
lacking the expression of pan-leukocyte markers
(CD45–) [18]. Further characterization of these cells
revealed immunophenotypic features previously de-
scribed to be associated with MSCs (e.g., CD10, CD73,
CD90, CD146, CD271, MSCA-1, SSEA-4 and STRO-1
expression) [1, 18]. In fact, the immunophenotypic
pattern of these CD13high CD105+ CD45– BM cells is
fully compatible with the widely described MSC profile,
Fig. 2 Growth kinetics (a) and immunophenotypic features (b–h) of mesenchymal stem cells (MSCs) obtained from BM mononuclear cells (MNCs)
using a standard protocol for in vitro MSC expansion compared to the growth kinetics of FACS-sorted and in vitro cultured CD13high CD105+
CD45– BM cells (identified as CD13high cells). a Bars and vertical lines correspond to median ± 95 % confidence interval values. b–h Notched
boxes extend from the 25th to 75th percentile values; the lines in the middle and vertical lines correspond to median values and both the
10th and 90th percentiles, respectively. Normalized median fluorescence intensity (MFI) values are displayed after subtracting the background
autofluorescence levels observed for each individual marker-associated fluorochrome channel (arbitrary units scaled from 0 to 262,000). NS not
significant (P > 0.05)
Muñiz et al. Stem Cell Research & Therapy  (2015) 6:169 Page 8 of 12except for the expression of HLA-DR which was found to
be systematically expressed in all or a substantial fraction
of all ex vivo studied CD13high CD105+ CD45– BM cells.
Of note, HLA-DR has been previously reported to be
absent on MSCs unless they had been stimulated (e.g., by
interferon-γ) [18, 48]. CD13high CD105+ CD45– cells were
isolated using a large set of markers, defined upon their
ex vivo characterization in a large number of BM samples,
in order to ensure a high cell purity. Based on this, sorted
CD13high CD105+ CD45– BM cells showed similar growth
kinetics, plastic adherence ability and osteogenic, adipo-
genic and chondrogenic differentiation potential as com-
pared to those exhibited by donor-matched MSCs isolatedusing conventional in vitro culture methods. These
results suggest that, in fact, this minor ex vivo BM
CD13high CD105+ CD45– cell population corresponded
to multipotent MSCs. In contrast, no adherent cells
with MSC functions were observed in the BM cell frac-
tion depleted on this specific minor cell population.
These findings suggest that the CD13high CD105+ CD45–
phenotype would identify the overall MSC population.
Alternatively, MSCs could consist of a heterogeneous cell
population which includes a pool of different cells with
distinct proliferation and differentiation capacities [32],
the MSCs not fulfilling the CD13high CD105+ CD45– cri-
teria potentially displaying a lower proliferation and/or
Fig. 3 (See legend on next page.)
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Fig. 3 The functional features of mesenchymal stem cells (MSCs) observed in vitro after culture of Biocoll isolated mononuclear cells (MNCs) with
conventional standard plastic adherence methods (left panels) versus FACS-purified and cultured CD13high CD105+ CD45– BM cells (right panels).
Panels Ia and Ib show undifferentiated and unstained MSCs cultured for 24 days (passage 3). Panels II through V display cells which have been
induced to differentiate in vitro towards the osteogenic (Panels II and III), adipogenic (Panels IV) and chondrogenic (Panels V) differentiation pathways.
Osteogenic differentiation was assessed using alkaline phosphatase (Panel II) and alizarin red S (Panel III) stainings at days +8 and +11, respectively;
adipogenesis was determined using the oil red O staining at day +8 (Panel IV), and chondrogenesis was evaluated by toluidine blue staining
at day +27 (Panel V). For each staining technique in Panels II–IV, undifferentiated controls counterstained with hematoxylin are also displayed
(Panels a and c)
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consequently, requiring more time and/or distinct culture
conditions to expand.
Of note, when immunophenotypic studies were re-
peated on expanded MSC fractions, no differences were
observed between donor-matched in vitro cultured
MSCs which had been isolated from the BM by the con-
ventional density gradient (e.g. Biocoll) purification
followed by plastic adherence method and in vitro ex-
panded CD13high CD105+ CD45– (FACS-purified) cells.
Interestingly, both in vitro expanded cell populations
lacked expression of HLA-DR (previously detected on
the CD13high CD105+ CD45– cells from all samples
studied ex vivo), suggesting the ex vivo identified
CD13high CD105+ CD45– cells in fact fulfill all minimal
criteria for the definition of MSCs, since such immuno-
phenotypic criteria were established on cultured cells
[18]. In addition, since HLA-DR is known to be
expressed on in vitro expanded MSCs upon activation
[48], it could be argued that, for example, the BM ex-
traction process could lead to activation of these cells,
which could “return” to a resting state upon stabilization
in culture. However, when both in vitro expanded frac-
tions of MSCs were compared with their donor-matched
ex vivo CD13high CD105+ CD45– cell population, for the
remaining MSC markers, significantly higher expression
levels were detected for CD105 and CD146 among the
cultured cells, in association with lower CD10 and CD13
expression. These immunophenotypic differences may
contribute to explain the lack of consensus regarding the
antigenic profile (and also morphological characteristics)
of BM MSCs in vivo, and at the same time they would
support previous results suggesting in vitro modulation
of the expression of several MSC-related markers (e.g.,
HLA-DR or CD146) after long-term cell culture [20, 21],
particularly when different culture conditions are used
for MSC expansion (e.g., CD10, CD73, CD90, CD105,
CD146) [44, 49], or the processes associated with cell
adherence and growth on plastic (e.g., CD44, CD34) var-
ies [28, 50]. Such in vitro antigen expression-associated
changes may potentially contribute to explain also some
of the discrepancies reported in the literature as regards
the genetic, phenotypic and functional properties of
in vitro cultured MSCs [17, 22–27]. Consequently, thehere described CD13high CD105+ CD45– MSC-specific
phenotype may contribute to a more accurate and stan-
dardized ex vivo characterization of MSCs, and a better
understanding of the in vivo biological and functional
features of this cell population, therefore contributing
also to establish more accurately the normal versus al-
tered MSC immunophenotypic transcriptional and func-
tional profiles in different disease conditions. Further
studies, in larger series of BM samples from patients
with distinct disease conditions, are necessary to fully
characterize these cells and to determine whether the
expression of CD13, CD105 and CD45 is stable enough
to be used as a backbone combination for the identifi-
cation and characterization of BM MSCs in patients
with distinct hematological malignancies and other
hematological and nonhematological disorders.
Conclusions
In summary, here we demonstrate for the first time that
BM MSCs can be identified ex vivo in normal/reactive
BM, based on a robust CD13high CD105+ and CD45–
inmunophenotypic profile. In addition, we also show
that in vitro expansion of these cells is associated with
significant changes in the immunophenotypic profile of
MSCs. Further studies are needed for more detailed
ex vivo characterization of these cells as a basis for the
identification of altered genotypes and phenotypes in
BM MSCs from patients diagnosed with different disease
conditions, such as myeloid and lymphoid malignancies.
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